New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:07 EDTXNCRXencor's asthma candidate shows posive results in preclinical study
Xencor will present preclinical data comparing activity of XmAb7195 to omalizumab in reducing IgE, a protein responsible for triggering disease activity in asthma and other allergic disorders. The study supports future studies in human clinical trials. The results of the study found that after a single 5 mg/kg intravenous dose of XmAb7195 or omalizumab in chimpanzees, XmAb7195 reduced free IgE to at least 10-fold lower levels than omalizumab. Similar to its effects in humans, omalizumab increased total IgE. In contrast, XmAb7195 rapidly depleted total IgE below quantifiable levels within 1 hour.
News For XNCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
16:10 EDTXNCRXencor backs view of sufficient funds for R&D, operations through 2016
Subscribe for More Information
16:09 EDTXNCRXencor renegotiates XmAb5871 agreement with Amgen
Xencor (XNCR) announced that it has regained all development and commercial rights to XmAb5871 by seeking and obtaining a termination of the prior option and collaboration agreement and executing a new right-of-first-negotiation agreement with Amgen (AMGN). XmAb5871 is a first-in-class monoclonal antibody containing Xencor's proprietary immune inhibitor XmAb Fc domain that targets FcăRIIb to inhibit B-cell function. XmAb5871 is currently in a Phase 1b/2a clinical trial in patients with moderate-to-severe rheumatoid arthritis and topline results are expected by the end of 2014. The company is planning clinical development in multiple autoimmune diseases where B-cell inhibition shows promise, including IgG4-related disease. Bassil Dahiyat, president and CEO of Xencor, said, "We determined that even with positive data following completion of the ongoing Phase 1b/2a trial in rheumatoid arthritis, refocusing our development plan on other autoimmune diseases would align better with Xencor's strategy to develop therapies for diseases with the highest unmet need. We approached Amgen to end the original collaboration to allow Xencor the freedom to pursue alternative clinical and commercial paths. Amgen agreed, provided we grant them a right of first negotiation for a license to XmAb5871. We plan to start clinical testing in IgG4-related disease in 2015. We do not plan on starting a Phase 2b rheumatoid arthritis trial in 2015...This agreement enables Xencor to regain rights to our Phase 2 asset and pursue what we feel is a stronger clinical development plan while maintaining our previously stated financial expectation that we will have sufficient cash to fund research and development programs and operations through 2016. We expect to have 2014 year-end cash and cash equivalents of approximately $54M."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use